In our analysis, there was a very similar relative benefit of crizotinib in ALK+ and pooled ROS1+ NSCLC populations (HR = 0.48), but slightly longer absolute survival in ROS1+ NSCLC. Here, ROS1 is linked to non-small cell lung carcinoma.